Entrada's DMD readout underwhelms, sparking a sharp stock slide
Entrada Therapeutics' first readout for ENTR-601-44 in Duchenne muscular dystrophy showed a 2.36% dystrophin increase over baseline 4%, well below analysts' 10–14% targets and rival del-zota's ~25%, triggering a roughly 59% drop in the stock to $6.57. Management attributed the miss to lower-than-expected plasma exposure in juvenile DMD patients (about 50% of adult exposure). New juvenile NHP data hint at a nonlinear exon-skipping response at higher levels, suggesting the second dose cohort could see a disproportionate jump in exon skipping. The company plans a third dose cohort and a higher-dose readout in Q4 to gauge whether ENTR-601-44 can rebound.